Director Of Business Development - Emea
CurrentHeartSciences mission is to enable accurate, affordable screening for the early detection of heart disease. Using wavelet mathematics and artificial intelligence, MyoVista® wavECG™ technology advances cardiac screening capabilities by measuring myocardial energy to identify repolarization abnormalities and cardiac dysfunction, even in asymptomatic patients. MyoVista wavECG bridges the “diagnostic gap” in cardiac care, providing a new low-cost solution that helps identify at-risk patients prior to an adverse cardiac event. MyoVista: The Power of Wavelet Signal Processing.